Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Albumin Solution Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

GLASSIA Infusion Rate Study

NCT01651351
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency, Healthy Volunteers
Interventions
Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 21, 2026, 5:45 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Trimodulin, Placebo (human albumin 1%)
Drug
Lead sponsor
Biotest
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

NCT04935359
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
NIS793, Nab-paclitaxel, Gemcitabine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Fayetteville, Arkansas • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

NCT03473223
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apolipoprotein A-I [human] (apoA-I), Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
18,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
202
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 21, 2026, 5:45 AM EDT
Terminated Phase 3 Interventional Results available

Albumin in Acute Ischemic Stroke Trial

NCT00235495
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Albumin, Saline
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 83 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
69
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Early Phase 1 Interventional

Carbamylation in Renal Disease-modulation With Amino Acid Therapy

NCT01612429
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Amino acid supplementation
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites

NCT03451292
View directory record Official record
Conditions
Decompensated Cirrhosis and Ascites
Interventions
Albutein 20%, SMT
Drug · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Coronado, California • Miami, Florida • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 21, 2026, 5:45 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study

NCT01394978
View directory record Official record
Conditions
Lung Cancer, Lung Tumor
Interventions
Control, ProGEL Pleural Air Leak Sealant with standard surgical closure, ProGEL Pleural Air Leak Sealant without standard surgical closure
Other · Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Jacksonville, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

NCT02436668
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Ibrutinib, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Huntsville, Alabama • Avondale, Arizona • Daly City, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

NCT00666263
View directory record Official record
Conditions
Multifocal Motor Neuropathy
Interventions
Immune Globulin Intravenous (human), 10%, 0.25% human albumin solution (Placebo)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Centennial, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 21, 2026, 5:45 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor Anguli Oris

NCT04240535
View directory record Official record
Conditions
Aging
Interventions
OnabotulinumtoxinA 50 UNT [Botox Cosmetic]
Drug
Lead sponsor
Amir Moradi MD, MBA
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 21, 2026, 5:45 AM EDT
Withdrawn Phase 2 Interventional

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

NCT04450654
View directory record Official record
Conditions
Immune-Mediated Necrotizing Myopathy
Interventions
Gamunex-C, Albumin
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure

NCT02120014
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
blood volume measurement, venous plethysmography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Trial of Carbamylation in Renal Disease-Modulation With Amino Acid Therapy

NCT02472834
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Amino acid supplementation NephrAmine®
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 21, 2026, 5:45 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

NCT02956122
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
GLASSIA, methylprednisolone or equivalent steroid, Albumin
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

NCT03421353
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
AZD9150, Durvalumab, Cisplatin, 5-Flourouracil, Carboplatin, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 21, 2026, 5:45 AM EDT
Terminated Not applicable Interventional Results available

VeraFlo With Prontosan® and Wound and Fracture Healing.

NCT02621073
View directory record Official record
Conditions
Infection
Interventions
VeraFlo with Prontosan, V.A.C Ulta System
Drug · Device
Lead sponsor
Brett Crist
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

NCT04167514
View directory record Official record
Conditions
Graft Versus Host Disease (GVHD)
Interventions
Alpha-1 antitrypsin (AAT), Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Stanford, California • Gainesville, Florida • Tampa, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Terminated Phase 2Phase 3 Interventional

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

NCT03805789
View directory record Official record
Conditions
Acute-graft-versus-host Disease
Interventions
AAT, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Endothelial Function After Cardiac Surgery

NCT02882074
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Human albumin, Hydroxyethyl starch
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 21, 2026, 5:45 AM EDT
Recruiting Not applicable Interventional

Initial Resuscitation for Acute Kidney Injury in Cirrhosis

NCT06525623
View directory record Official record
Conditions
Cirrhosis, Liver, Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Recommendation: No Further Resuscitation, Recommendation: Resuscitation with Crystalloid, Recommendation: Resuscitation with Colloid, Recommendation: Standard of Care IV Albumin
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1Phase 2 Interventional

IVIG - West Nile Encephalitis: Safety and Efficacy

NCT00068055
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-lgG-am, Polygam® S/D, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

NCT01615484
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
Procedure · Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 21, 2026, 5:45 AM EDT